9月22日，Viking Therapeutics盘中上涨34.37%，报40.445美元/股，成交额6.95亿美元。
消息面上，公司公布其GLP-1/GIP双激动剂VK2735维持期研究积极顶线数据。研究显示，在诱导期结束后将给药频率从每周一次降至每两周一次，患者在12周内仍维持了高达97%的减重效果；月度给药方案下亦可保留高达90%的平均减重成果。此外，在每周17.5毫克剂量下，第33周安慰剂调整后体重降幅达22%，药物安全性和耐受性表现良好。公司计划在研究第二部分探索口服给药方案。该数据进一步验证了VK2735在快速扩张的减肥药市场中的竞争潜力。
Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.